catalog number :
MBS127968
products full name :
PAI-1 Polyclonal Antibody
products short name :
[PAI-1]
products name syn :
[SERPINE1; PAI; PAI-1; PAI1; PLANH1; Plasminogen activator inhibitor1; Endothelial plasminogen activator inhibitor; Serpin E1]
other names :
[Plasminogen activator inhibitor 1; Plasminogen activator inhibitor 1; plasminogen activator inhibitor 1; serpin E1; endothelial plasminogen activator inhibitor; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; Endothelial plasminogen activator inhibitor; Serpin E1]
products gene name :
[SERPINE1]
other gene names :
[SERPINE1; SERPINE1; PAI; PAI1; PAI-1; PLANH1; PAI1; PLANH1; PAI; PAI-1]
uniprot entry name :
PAI1_HUMAN
reactivity :
Human, Mouse, Rat
purity :
Affinity Purification
storage stability :
Store at 4 degree C. Avoid freeze / thaw cycles.
tested application :
Western Blot (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP)
app notes :
WB 1:500 - 1:1000
image1 heading :
Western Blot (WB)
other info1 :
Species: Human. Route: Synthetic Peptide
other info2 :
Immunogen: A synthetic peptide of human SERPINE1. Buffer: PBS with 0.02% sodium azide, pH7.3.
products categories :
Polyclonal
products description :
PAI-1 is a secreted protein that belongs to the serine proteinase inhibitor (serpin) superfamily. It inhibits urokinase and tissue plasminogen activators (uPA and tPA) and thus, reduces the conversion of inactive plasminogen to plasmin (1). PAI-1 regulates fibrinolysis and plays an important role in vessel patency and tissue remodeling. Secreted PAI-1 interacts with the extracellular matrix (ECM) component vitronectin, thereby modulating cell-ECM interactions (2,3). PAI-1 is expressed in a variety of tissues with higher expression in liver, vascular endothelial cells, platelets, macrophages, and adipose tissue (1). Increased levels of PAI-1 are associated with deep vein thrombosis (4). Defects in PAI-1 cause plasminogen activator inhibitor-1 deficiency (PAI-1D), which is characterized by increased bleeding after injury or surgery (5). Research studies have shown that high levels of PAI-1 are associated with obesity, aging, insulin resistance, and type 2 diabetes (6-8). PAI-1 is transcriptionally regulated by TGF-beta and mediates TGF-beta-induced inhibition of cell migration and invasion in cancer cells (9). Studies have shown PAI-1 to be also involved in fibrosis (10).
ncbi mol weight :
Calculated MW: 43kDa/45kDa. Obserd MW: 45 kDa
ncbi pathways :
Adipogenesis Pathway (198832); BMAL1:CLOCK,NPAS2 Activates Circadian Gene Expression Pathway (477138); Blood Clotting Cascade Pathway (198840); Chagas Disease (American Trypanosomiasis) Pathway (147809); Chagas Disease (American Trypanosomiasis) Pathway (147795); Circadian Clock Pathway (187173); Complement And Coagulation Cascades Pathway (198880); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484); Direct P53 Effectors Pathway (137939)
ncbi summary :
This gene encodes a member of the serine proteinase inhibitor (serpin) superfamily. This member is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2009]
uniprot summary :
SERPINE1: a secreted protein that acts as bait for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis. Belongs to the serpin family. Interacts with VTN. Binds LRP1B; binding is followed by internalization and degradation. Plasma levels of PAI-1 and VCAM-1 together may be useful in predicting post-operative recurrence in patients with colorectal cancer. Protein type: Motility/polarity/chemotaxis; Secreted, signal peptide; Secreted. Chromosomal Location of Human Ortholog: 7q22.1. Cellular Component: extracellular matrix; extracellular space; plasma membrane; extracellular region. Molecular Function: serine-type endopeptidase inhibitor activity; protein binding; protease binding; receptor binding. Biological Process: circadian rhythm; platelet activation; transcription initiation from RNA polymerase II promoter; extracellular matrix organization and biogenesis; positive regulation of blood coagulation; transcription, DNA-dependent; negative regulation of blood coagulation; negative regulation of smooth muscle cell migration; defense response to Gram-negative bacterium; positive regulation of receptor-mediated endocytosis; regulation of cell proliferation; positive regulation of interleukin-8 production; fibrinolysis; positive regulation of angiogenesis; negative regulation of fibrinolysis; platelet degranulation; transforming growth factor beta receptor signaling pathway; positive regulation of transcription from RNA polymerase II promoter; gene expression; regulation of receptor activity; angiogenesis; blood coagulation; chronological cell aging; negative regulation of cell migration; negative regulation of cell adhesion mediated by integrin; positive regulation of inflammatory response. Disease: Plasminogen Activator Inhibitor-1 Deficiency